综合性心血管疾病治疗:酸限制,增强的外部对冲,以及新兴的纳米疗法
1Midwestern University, Downers Grove, IL 60515, United States. drm@mercola.com.
World journal of cardiology
|September 15, 2025
概括
新的心血管疾病策略针对炎症和内皮功能障碍等根本原因,旨在显著减少主要心血管不良事件 (MACE) 并改善患者的治疗结果.
科学领域:
- 心血管医学 心血管医学
- 翻译科学 翻译科学
- 预防性心脏病学 预防性心脏病学
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因,尽管目前的治疗方法仍然存在残留风险.
- 像PCI和他类药物这样的现有干预措施对重大心血管不良事件 (MACE) 提供有限的保护,留下了大量未满足的需求.
- 目前的治疗方法专注于光线狭窄,忽视了动脉样硬化的全身驱动因素,如内皮功能障碍和炎症.
研究的目的:
- 探索针对潜在的动脉动脉生成驱动因素的新型治疗策略,以减少残留心血管风险.
- 评估创新方法,包括饮食修改,增强外部对冲和基于纳米粒子的化.
- 评估这些干预措施在缓解炎症,改善内皮功能和稳定动脉样硬化斑块方面的潜力.
主要方法:
- 饮食中酸的限制 (<5克/天),以减少氧化LDL和动脉炎症.
- 增强的外部反推力 (EECP) 通过脉动剪切应力改善冠状动脉 perfusion.
- 纳米颗粒促进化为有针对性的斑块减少.
主要成果:
- 酸的限制使氧化LDL降低了15%,减轻了动脉炎症.
- 在约70%的耐火病例中,EECP缓解了心痛.
- 在临床前模型中,纳米颗粒化可使斑块量降低高达30%.
- 这些方法解决了剩余的风险因素,可能使MACE率减半.
结论:
- 针对内皮功能障碍,炎症和斑块不稳定的新策略为减少残留心血管风险提供了有希望的方法.
- 饮食中氨酸限制,EECP和纳米颗粒化代表了心血管疾病管理的创新途径.
- 进一步的临床试验至关重要,以验证这些有希望的干预措施的长期安全性和可扩展性,以改变心血管疾病护理.
相关概念视频
Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322
Peripheral Artery Disease III: Interprofessional Care
248
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
248
Heart Failure VI: Adjunct Therapies
261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261
Cardiomyopathy V: Interprofessional Care
339
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
339
Rheumatic Heart Disease III: Medical Management
289
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
289
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
441
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441

